Market Research Logo

Rheumatoid Arthritis Therapeutics in Asia-Pacific Markets to 2023 - Novel JAK and IL-6 Receptor Inhibitors to Stimulate Moderate Growth Despite Launch of Biosimilars of Blockbuster Anti-TNFs

Rheumatoid Arthritis Therapeutics in Asia-Pacific Markets to 2023 - Novel JAK and IL-6 Receptor Inhibitors to Stimulate Moderate Growth Despite Launch of Biosimilars of Blockbuster Anti-TNFs

Summary


Rheumatoid Arthritis (RA) is a chronic, progressive and currently incurable autoimmune disease that primarily affects the joints. It is characterized by synovial inflammation and gradual bone erosion over many years. Disease progression results in stiffness and pain, especially in the hands and feet, which hinders mobility. Without treatment, the disease leads to joint destruction and disability.

The chronic nature of the disease, which requires ongoing treatment, and the relatively high annual cost of therapy (ACoT) have made RA treatment a highly lucrative market. The RA therapeutic market has become very competitive due to the high number of new drug approvals. Competition is fierce, particularly among TNF-α inhibitors, which dominate the treatment market for RA patients who are refractory to traditional disease-modifying anti-rheumatic drugs (DMARD).

Despite this, 30% of RA patients fail to attain a clinical response when treated with TNF-α inhibitors. However, other targeted programs, as well as newly marketed small-molecule DMARDs such as the Janus kinase (JAK) inhibitor Xeljanz (tofacitinib), have the potential to replace ineffective TNF-α inhibitors. Recently published study results of Xeljanz have shown a significant reduction in the risk of developing cardiac diseases such as heart attack and stroke in patients with RA.

The advent of biologic disease-modifying anti-rheumatic drugs (DMARD) has boosted the rheumatoid arthritis (RA) market tremendously over the last two decades. Growth is expected to continue at a moderate pace from around $5.6 billion in 2016 to more than $9.5 billion in 2023 at a compound annual growth rate (CAGR) of over 8% in the Asia-Pacific (APAC) markets of India, Australia, China, South Korea and Japan. Japan accounted for the majority of the market in 2016 with a 65.4% share, followed by China, Australia, India and South Korea with about 12.7%, 8.6%, 8.1% and 5.2% respectively.

Recently approved therapies anticipated to have a high impact include Eli Lilly and Incyte’s baricitinib and Sanofi and Regeneron’s sarilumab. Along with recently approved therapies, the entry of new therapies over the forecast period will stimulate market growth. Promising pipeline candidates include Johnson & Johnson (J&J) and GlaxoSmithKline (GSK)’s sirukumab, and Galapagos’s filgotinib. Galapagos entered into a global collaboration agreement with Gilead in 2015 to develop and commercialize filgotinib for the treatment of inflammatory indications.

The report Rheumatoid Arthritis Therapeutics in Asia-Pacific Markets to 2023 - Novel JAK and IL-6 Receptor Inhibitors to Stimulate Moderate Growth Despite Launch of Biosimilars of Blockbuster Anti-TNFs provides the current Asia-Pacific RA market contains novel products, including sirukumab, an anti-IL-6 human mAb; Peficitinib, Upadacitinib and Filgotinib, which are JAK1 inhibitors; Olokizumab, an anti-IL-6 humanized IgG4 mAb; and RCT-18, a recombinant human B-lymphocyte stimulating factor (BLyS) receptor-antibody fusion protein.

Scope

The current Asia-Pacific RA market contains novel products, including sirukumab, an anti-IL-6 human mAb; Peficitinib, Upadacitinib and Filgotinib, which are JAK1 inhibitors; Olokizumab, an anti-IL-6 humanized IgG4 mAb; and RCT-18, a recombinant human B-lymphocyte stimulating factor (BLyS) receptor-antibody fusion protein.

  • What are the competitive advantages of the existing novel drugs?
  • There are over 480 active pipeline molecules, and most of the late-stage investigational drug candidates feature improved dosing regimens and administration routes in comparison to currently marketed products and combination therapies.
  • Which classes of novel drugs are most prominent in the pipeline?
  • What is the potential for pipeline products to address unmet needs in the RA market?
  • Analysis of clinical trials since 2006 identified that the failure rates of RA molecules were highest in Phase II, at 72.6%, with the overall attrition rate for RA standing at 94.6%.
  • How do failure rates vary by stage of development, molecule type, and molecular target?
  • How do other factors, such as average trial duration and trial size, influence the costs and risks associated with product development?
Over the 2016-2023 forecast period, the Asia-Pacific RA therapeutics market is expected to increase in value at a compound annual growth rate of 8.2%, from $5.6 billion to over $9.7 billion.
  • Which markets make the most significant contribution to the current market size?
  • What are the epidemiology trends in these markets?
  • Will new market entrants lead to substantial changes in annual therapy costs?
  • How will different treatment usage patterns impact growth in the five assessed Asia-Pacific markets?
A rising RA prevalence population and the uptake of newer therapies will lead to significant market growth over the forecast period, despite the launch of biosimilars of blockbuster anti-TNFs.
  • Will the launch of biosimilars or emerging pipeline molecules threaten the commercial success of existing drugs?
  • Licensing deals are the most common form of strategic alliance in the RA therapeutics market, with deal values ranging from under $10m to over $1 billion.
  • How do deal frequency and value compare between target families and molecule types?
  • What were the terms and conditions of key licensing deals?
Reasons to buy
  • Understand the clinical context of RA by considering epidemiology, symptoms, etiology and pathophysiology, diagnosis, prognosis, treatment guidelines and options, and biologic registries.
  • Identify the therapeutic strategies, products, and companies that dominate the current marketed products landscape and recognize gaps and areas of unmet need.
  • Identify key pipeline trends in terms of molecule type, administration route, molecular target, and novelty.
  • Consider market opportunities and potential risks by examining trends in RA clinical trial size, duration, and failure rate by stage of development, molecule type, and molecular target.
  • Recognize the late-stage pipeline molecules that have demonstrated strong therapeutic potential in RA by examining clinical trial data and multi-scenario product forecast projections.
  • Compare treatment usage patterns, annual therapy costs, and market growth projections for India, China, Australia, Japan and South Korea.
  • Discover trends in licensing and co-development deals concerning RA products and identify the major strategic consolidations that have shaped the commercial landscape.


  • GBI Research Report Guidance
  • Executive Summary
  • Introduction
    • Disease Introduction
    • Epidemiology
      • Table Figure 1: RA Therapeutics Market, Australia, Age-Specific Prevalence (%), 2014-2015
    • Symptoms
    • Etiology and Pathophysiology
    • Diagnosis
      • Physical Examination
      • Blood Tests
      • 1987 Rheumatoid Arthritis Classification
      • 2010 ACR-EULAR Classification Criteria for Rheumatoid Arthritis
        • Table ACR-EULAR Classification Criteria for Rheumatoid Arthritis, 2010
    • Prognosis
    • Treatment Guidelines and Options
      • Table Figure 2: American College of Rheumatology Treatment Guidelines, 2015
      • Table Figure 3: European League Against Rheumatism Treatment Guidelines, 2016
      • Pharmacological
      • Methotrexate
      • Hydroxychloroquine
      • Leflunomide
      • Sulfasalazine
      • Cyclosporine
      • Xeljanz (tofacitinib)
      • Other Non-biologics
      • Biologic Disease-Modifying Anti-rheumatic Drugs
      • Disease Scoring Methods for Measuring Treatment Efficacy
    • Co-morbidities and Complications
  • Marketed Products
    • Overview
    • Small-Molecule Disease-Modifying Anti-rheumatic Drugs
      • Methotrexate-Based Products
      • Xeljanz (tofacitinib) - Pfizer
    • Biologic Disease-Modifying Anti-rheumatic Drugs
      • Remicade (infliximab) - Johnson & Johnson
      • Humira (adalimumab) - AbbVie
      • Enbrel (etanercept) - Amgen
      • Rituxan/MabThera (rituximab) - Biogen Idec and Genentech
      • Orencia (abatacept) - Bristol-Myers Squibb
      • Simponi (golimumab) - Johnson & Johnson, Merck
      • Cimzia (certolizumab pegol) - UCB
      • Actemra (tocilizumab) - Roche
      • Olumiant (baricitinib) - Eli Lilly
      • Kevzara (Sarilumab) - Regeneron/Sanofi
      • Prolia (denosumab) - Amgen/Daiichi Sankyo
    • Comparative Efficacy and Safety of Marketed Products
      • Conventional Synthetic Disease Modifying Anti-rheumatic Drugs (csDMARDs)
        • Table Figure 4: RA Therapeutics Market, Comparative Efficacy and Safety Heatmap for Conventional Synthetic Disease Modifying Anti-rheumatic Marketed Products
      • Anti-TNF- Biologic Disease Modifying Anti-rheumatic Drugs (bDMARDs)
        • Table Figure 5: RA Therapeutics Market, Comparative Efficacy and Safety Heatmap for Anti TNF- Biologic Disease Modifying Anti-rheumatic Marketed Products
      • Non-anti-TNF- Biologic Disease Modifying Anti-rheumatic Drugs
        • Table Figure 6: RA Therapeutics Market, Comparative Efficacy and Safety Heatmap for Non-TNF- Biologic Disease Modifying Anti-rheumatic Marketed Products
      • Targeted Synthetic Disease Modifying Anti-rheumatic Drugs
        • Table Figure 7: RA Therapeutics Market, Comparative Efficacy and Safety Heatmap for Targeted Synthetic Disease Modifying Anti-rheumatic Marketed Products
  • Product Pipeline
    • Overview
    • Pipeline Distribution by Phase of Development, Molecule Type, Route of Administration and Novelty
      • Table Figure 8: RA Therapeutics Market, Global, Pipeline, 2016
    • Pipeline Distribution by Molecular Target
      • Table Figure 9 RA Therapeutics Market, Global, Pipeline by Molecular Target, 2016
      • Table Figure 10: RA Therapeutics Market, Global, Pipeline by Molecular Target and Stage of Development, 2016
    • Promising Pipeline Candidates
      • Sirukumab - Johnson & Johnson
        • Table Figure 11: RA Therapeutics Market, APAC, Sirukumab Forecast ($m), 2018-2023
      • Peficitinib - Astellas
        • Table Figure 12: RA Therapeutics Market, APAC, Peficitinib Forecast ($m), 2019-2023
      • Upadacitinib - AbbVie
        • Table Figure 13: RA Therapeutics Market, APAC, Upadacitinib Forecast ($m), 2022-2023
      • Filgotinib - Galapagos
        • Table Figure 14: RA Therapeutics Market, APAC, Filgotinib Forecast ($m), 2020-2023
      • Olokizumab - R-Pharm
      • RCT-18 - Yantai RC-Pharma
    • Comparative Efficacy and Safety of Pipeline Products
      • Table Figure 15: RA Therapeutics Market, Comparative Efficacy and Safety Heatmap for Pipeline Products
    • Product Competitiveness Framework
      • Table Figure 16: RA Therapeutics Market, Competitor Matrix for RA Marketed and Pipeline Products, 2017
  • Clinical Trial Analysis
    • Failure Rate
      • Overall Failure Rate
        • Table Figure 17: RA Therapeutics Market, Global, Average Clinical Trial Failure Rate (%), 2016
      • Failure Rate by Phase and Molecule Type
        • Table Figure 18: RA Therapeutics Market, Global, Clinical Trial Failure Rate by Molecule Type (%), 2006-2016
      • Failure Rate by Phase and Molecular Target
        • Table Figure 19: RA Therapeutics Market, Global, Clinical Trial Failure Rate by Molecular Target (%), 2006- 2016
    • Clinical Trial Duration
      • Clinical Trial Duration by Molecule Type
        • Table Figure 20: RA Therapeutics Market, Global, Clinical Trial Size per Product by Stage of Development and Molecule Type, 2006-2016
      • Clinical Trial Duration by Molecular Target
        • Table Figure 21: RA Therapeutics Market, Global, Clinical Trial Duration by Molecular Target, 2006-2016
    • Clinical Trial Size
      • Patient Enrollment per Product by Molecule Type, Molecular Target and Stage of Development
        • Table Figure 22: RA Therapeutics Market, Global, Clinical Trial Size per Product by Molecule Type, 2006-2016
        • Table Figure 23: RA Therapeutics Market, Global, Clinical Trial Size per Product by Molecular Target, 2006- 2016
      • Patient Enrollment per Trial by Molecule Type, Molecular Target and Stage of Development
        • Table Figure 24: RA Therapeutics Market, Global, Clinical Trial Size per Trial by Molecular Type, 2006-2016
        • Table Figure 25: RA Therapeutics Market, Global, Clinical Trial Size per Trial by Molecular Target, 2006-2016
    • Summary of Clinical Trial Metrics
      • Table Figure 26: RA Therapeutics Market, Comparison of Average Trial Metrics by Phase and Molecule Type
      • Table Figure 27: RA Therapeutics Market, Comparison of Average Trial Metrics by Phase and Molecular Target
  • Multi-Scenario Forecast
    • Geographical Markets
    • APAC Markets
      • Table Figure 28: RA Therapeutics Market, Asia Pacific, Treatment Usage Patterns (million), 2016-2023
      • Table Figure 29: RA Therapeutics Market, Asia Pacific, Market Size ($bn), 2016-2023
    • India
      • Treatment Usage Patterns
        • Table Figure 30: RA Therapeutics Market, India, Treatment Usage Patterns ('000), 2016-2023
      • Annual Cost of Therapy
        • Table Figure 31: RA Therapeutics Market, India, Annual Cost of Therapy ($), 2016-2023
      • Market Size
        • Table Figure 32: RA Therapeutics Market, India, Market Size ($m), 2016-2023
    • China
      • Treatment Usage Patterns
        • Table Figure 33: RA Therapeutics Market, China, Treatment Usage Patterns (`000), 2016-2023
      • Annual Cost of Therapy
        • Table Figure 34: RA Therapeutics Market, China, Annual Cost of Therapy ($), 2016-2023
      • Market Size
        • Table Figure 35: RA Therapeutics Market, China, Market Size ($m), 2016-2023
    • Australia
      • Treatment Usage Patterns
        • Table Figure 36: RA Therapeutics Market, Australia, Treatment Usage Patterns (`000), 2016-2023
      • Annual Cost of Therapy
        • Table Figure 37: RA Therapeutics Market, Australia, Annual Cost of Therapy ($), 2016-2023
      • Market Size
        • Table Figure 38: RA Therapeutics Market, Australia, Market Size ($m), 2016-2023
    • South Korea
      • Treatment Usage Patterns
        • Table Figure 39: RA Therapeutics Market, South Korea, Treatment Usage Patterns (`000), 2016-2023
      • Annual Cost of Therapy
        • Table Figure 40: RA Therapeutics Market, South Korea, Annual Cost of Therapy ($), 2016-2023
      • Market Size
        • Table Figure 41: RA Therapeutics Market, South Korea, Market Size ($m), 2016-2023
    • Japan
      • Treatment Usage Patterns
        • Table Figure 42: RA Therapeutics Market, Japan, Treatment Usage Patterns (`000), 2016-2023
      • Annual Cost of Therapy
        • Table Figure 43: RA Therapeutics Market, Japan, Annual Cost of Therapy ($), 2016-2023
      • Market Size
        • Table Figure 44: RA Therapeutics Market, Japan, Market Size ($m), 2016-2023
  • Market Dynamics (Drivers and Barriers) of RA Therapeutics Market
    • Drivers
      • Rising Prevalence in an Aging Population
      • Launch of Novel Drugs: Oral JAK Inhibitors and Novel Biologics
      • Increasing Awareness of RA
    • Barriers
      • Increasing Use of Complementary and Alternative Medicine
      • Launch of Cheaper Biosimilars
      • Unmet Needs for Efficacious Therapies Diminishing
  • Deals and Strategic Consolidations
    • Licensing Deals
      • Deals by Region and Value
        • Table Figure 45: RA Therapeutics Market, Global, Licensing Deals by Region and Value, 2006-2017
      • Number of Disclosed and Undisclosed Deals by Year, Aggregate Deal Value
        • Table Figure 46: RA Therapeutics Market, Global, Number of Disclosed and Undisclosed Licensing Deals by Year, Aggregate Deal Value and Aggregate Upfront Payment Value, 2006-2017
      • Deal Value by Stage of Development, Molecule Type and Molecular Target
        • Table Figure 47: RA Therapeutics Market, Global, Licensing Deals by Stage of Development, and Deal Value, 2006-2017
        • Table Figure 48: RA Therapeutics Market, Global, Licensing Deals by Molecule Type and Stage of Development, 2006-2017
        • Table Figure 49: RA Therapeutics Market, Global, Licensing Deals by Molecular Target and Aggregate Deal Value ($m), 2006-2017
      • Maruho Enters into Licensing Agreement with 4SC for a Preclinical Compound
      • CSL Enters into Licensing Agreement with Momenta Pharmaceuticals for M230 Preclinical Product Candidate
      • Mylan Enters into Licensing Agreement with Momenta Pharmaceuticals for Biosimilar Candidates
      • Ablynx Enters into a Licensing Deal with AbbVie for the Nanobody ALX-0061
        • Table RA Therapeutics Market, Global, Licensing Deals Valued over $10m, 2006-2017
    • Co-development
      • Deals by Region and Value
        • Table Figure 50: RA Therapeutics Market, Global, Co-development Deals by Region and Deal Value, 2006- 2017
      • Number of Disclosed and Undisclosed Deals by Year, Aggregate Deal Value
        • Table Figure 51: RA Therapeutics Market, Global, Number of Disclosed and Undisclosed Co-development Deals by Year, Aggregate Deal Value and Aggregate Upfront Payment Value, 2006-2017
      • Deal Value by Stage of Development, Molecule Type, and Molecular Target
        • Table Figure 52: RA Therapeutics Market, Global, Co-development Deals by Stage of Development, and Deal Value, 2006-2016
        • Table Figure 53: RA Therapeutics Market, Global, Co-development Deals by Molecule Type and Stage of Development, 2006-2017
        • Table Figure 54: Rheumatoid Arthritis Market, Global, Co-development Deals by Molecular Target, 2006-2017
      • Sanofi Enters into an Agreement with JHL Biotech
      • Gilead Sciences Enters into Co-development Agreement with Galapagos
      • Epirus Enters into an Agreement with Orygen Biotecnologia
      • Dynavax Enters into Co-development Agreement with GlaxoSmithKline
        • Table RA Therapeutics Market, Global, Co-development Deals Valued over $10m, 2006-2017
  • Appendix
    • All Pipeline Drugs by Stage of Development
      • Discovery
        • Table RA Therapeutics Market, Global, All Pipeline Products, Discovery, 2016
      • Preclinical
        • Table RA Therapeutics Market, Global, All Pipeline Products, Preclinical, 2016
      • Investigational New Drug/Clinical Trial Authorization-Filed
        • Table RA Therapeutics Market, Global, All Pipeline Products, Investigational New Drug, 2016
      • Phase I
        • Table RA Therapeutics Market, Global, All Pipeline Products, Phase I, 2016
      • Phase II
        • Table RA Therapeutics Market, Global, All Pipeline Products, Phase II, 2016
      • Phase III
        • Table RA Therapeutics Market, Global, All Pipeline Products, Phase III, 2016
      • Pre-registration
        • Table RA Therapeutics Market, Global, All Pipeline Products, Pre-registration, 2016
    • Summary of Multi-scenario Market Forecasts to 2023
      • Asia-Pacific
        • Table RA Therapeutics Market, APAC, Market Forecast, 2016-2023
      • India
        • Table RA Therapeutics Market, India, Market Forecast, 2016-2023
      • China
        • Table RA Therapeutics Market, China, Market Forecast, 2016-2023
      • Australia
        • Table RA Therapeutics Market, Australia, Market Forecast, 2016-2023
      • South Korea
        • Table RA Therapeutics Market, South Korea, Market Forecast, 2016-2023
      • Japan
        • Table RA Therapeutics Market, Japan, Market Forecast, 2016-2023
    • Bibliography
    • Abbreviations
    • Research Methodology
      • Secondary Research
      • Marketed Product Profiles
      • Late-Stage Pipeline Candidates
      • Comparative Efficacy and Safety Heat Map for Marketed and Pipeline Products
      • Product Competitiveness Framework
      • Pipeline Analysis
      • Clinical Trials
      • Clinical trial Endpoint Analysis
      • Forecasting Model
      • Deals Data Analysis
    • Contact Us
    • Disclaimer

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report